within the swiftly evolving area of cancer therapeutics, comprehending the intricate mechanisms of Antibody-Drug Conjugates (ADCs) is vital for acquiring productive remedies. Among the most promising methods is the use of in vitro bystander outcome assays, which play a pivotal role in maximizing therapeutic efficacy. These assays, provided by organ